Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LONP1 | P36776 | 9/20 | 0.65 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.65 |
| ▸ | PSMB11 | A5LHX3 | 5/20 | 0.65 |
| ▸ | PSMA7 | O14818 | 5/20 | 0.65 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.65 |
| ▸ | PSMA1 | P25786 | 5/20 | 0.65 |
| ▸ | PSMA2 | P25787 | 5/20 | 0.65 |
| ▸ | PSMA3 | P25788 | 5/20 | 0.65 |
| ▸ | PSMA4 | P25789 | 5/20 | 0.65 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.65 |
| ▸ | PSMB9 | P28065 | 5/20 | 0.65 |
| ▸ | PSMA5 | P28066 | 5/20 | 0.65 |
| ▸ | PSMB4 | P28070 | 5/20 | 0.65 |
| ▸ | PSMB6 | P28072 | 5/20 | 0.65 |
| ▸ | PSMB10 | P40306 | 5/20 | 0.65 |
| ▸ | PSMB3 | P49720 | 5/20 | 0.65 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.65 |
| ▸ | PSMA6 | P60900 | 5/20 | 0.65 |
| ▸ | PSMA8 | Q8TAA3 | 5/20 | 0.65 |
| ▸ | PSMB7 | Q99436 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837260 | 0.94 | LONP1 (0.60) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL21968901 | 0.94 | LONP1 (0.60) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL13928500 | 0.87 | LONP1 (0.66) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL463940 | 0.87 | LONP1 (0.60) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL446669 | 0.86 | LONP1 (0.62) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL14096685 | 0.86 | LONP1 (0.62) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL8306179 | 0.81 | LONP1 (0.58) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL3221086 | 0.81 | LONP1 (0.46) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL3221108 | 0.81 | LONP1 (0.46) | LONP1PSMB5PSMB11PSMA7PSMB1 | |
| SCHEMBL21968828 | 0.81 | SMN1; SMN2 (0.52) | LONP1PSMB5PSMB11PSMA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1636208-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | LONP1 151/4885PSMB5 357/4885PSMB11 414/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | LONP1 456/4885PSMB5 436/4885PSMB11 193/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | LONP1 456/4885PSMB5 436/4885PSMB11 193/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | LONP1 456/4885PSMB5 436/4885PSMB11 193/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | LONP1 540/4885PSMB5 606/4885PSMB11 347/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | LONP1 156/4885PSMB5 360/4885PSMB11 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.